 |
Lunch: 11:30 AM - 12:00 PM Unable to join us in New Orleans but still want to attend this CPE activity?
|
|
Program Overview:
Iron deficiency (ID), a common comorbidity in patients with heart failure (HF), is associated with significant adverse clinical outcomes, with or without the presence of anemia. These adverse consequences include a poorer quality of life and reduced exercise capacity, a higher risk of hospitalization, and increased mortality. ID is under-recognized, despite recommendations for routine testing of ferritin and transferrin saturation (TSAT) levels in guidelines. Oral iron has significant limitations, is ineffective in HF patients, and is not recommended in HF guidelines. Conversely, intravenous iron has been well-studied in numerous clinical trials and recommended in HF guidelines. One intravenous (IV) formulation, ferric carboxymaltose (FCM), has a specific indication for the treatment of patients with HF, and it has recently been evaluated in comprehensive meta-analyses for its effects on hard clinical outcomes. Therefore, in this program, to take place at the AMCP scientific sessions in New Orleans, LA, experts in ID in HF will explain to attendees key concepts of ID pathophysiology, identify the tests for diagnosis of ID and emphasize the importance of regular screening. Evidence with IV iron and guideline recommendations will be translated to clinical practice, illustrating the value of treating HF patients with ID with IV iron. The case will demonstrate the benefits of IV iron for HF patients with ID making them feel better (improving their HF symptoms, exercise capacity, and overall quality of life (QOL)) and keeping them out of the hospital. The case will align with an expert-generated algorithm published in a scientific statement on ID in HF from the Heart Failure Society of America (HFSA). |
|
|
Educational Objectives: Accreditation & Credit Designation:  Pharmacists: Postgraduate Healthcare Education, LLC is
accredited by the Accreditation Council for Pharmacy
Education (ACPE) as a provider of continuing pharmacy
education (CPE). This activity is accredited for 1.5 contact
hours of knowledge-based CPE under the ACPE universal activity
number 0430-9999-24-030-L01-P.
Educational Grant: Voxmedia International gratefully acknowledges the independent educational grant provided by American Regent. Disclosure Statement: Voxmedia strives to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose to Voxmedia all financial relationships for the preceding 24 months (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only after Voxmedia mitigates all financial relationships may faculty receive approval to participate, and are expected to contribute evidence-based material. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will disclose to learners that all relevant financial relationships have been mitigated in either written materials, visually and/or verbally. It remains for the audience to determine whether the speaker s interests or relationships may influence the presentation. Speakers must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices. | |
